Department of Medical Oncology, Cancer Center, the State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan Province, China.
Eur Rev Med Pharmacol Sci. 2019 Aug;23(16):6951-6961. doi: 10.26355/eurrev_201908_18735.
To explore the expression of circulating tumor cells (CTCs) and cyclooxygenase-2 (COX-2) in CTCs and to assess their association with clinical parameters and treatment.
Peripheral blood samples from 50 patients with nasopharyngeal carcinoma (NPC) were included. We applied advanced CanPatrolTM CTC enrichment technique and in situ hybridization assay to isolate, identify, and classify CTCs and COX-2 in CTCs. Epstein-Barr virus DNA was detected by Real Time-quantitative PCR (RT-qPCR).
No CTCs were identified in ten healthy volunteers (100%). Of the total patients, 48 (96%) had positive CTCs counts and 36 (72%) had positive mesenchymal CTCs counts before treatment. CTCs cells were highly expressed in different NPC stages, and the positive ratio of mesenchymal CTCs in stage IV was higher than that in other stages. The proportion of mesenchymal cells was higher expressed in metastasis patients. The expression of COX-2 was different in different types of CTCs. The positivity of COX-2 in CTCs was higher in stage IV patients than that in stage II and stage III patients. Decreased mesenchymal CTCs and that express COX-2 indicated a favorable curative effect in NPC patients. The positivity of mesenchymal CTCs and COX-2 was higher in EBV DNA positive patients compared with EBV DNA negative patients (p<0.05). Meanwhile, the mean number of CTCs, mesenchymal CTCs, CTCs that express COX-2, hybrid CTCs that express COX-2 and mesenchymal CTCs that express COX-2 was significantly higher in the EBV DNA positive patients than negative patients before treatment (p<0.05).
CTCs and their expression of COX-2 were correlated with NPC clinical characteristics, and have a relation with Epstein-Barr virus DNA. Decreased mesenchymal CTCs and that express COX-2 indicated a favorable curative effect in NPC patients.
探讨循环肿瘤细胞（CTCs）和环氧化酶-2（COX-2）在 CTCs 中的表达，并评估其与临床参数和治疗的关系。
纳入 50 例鼻咽癌（NPC）患者的外周血样本。我们应用先进的 CanPatrolTM CTC 富集技术和原位杂交技术分离、鉴定和分类 CTCs 和 CTCs 中的 COX-2。采用实时定量 PCR（RT-qPCR）检测 Epstein-Barr 病毒 DNA。
10 名健康志愿者（100%）均未检出 CTCs。在所有患者中，48 例（96%）治疗前 CTCs 计数阳性，36 例（72%）间充质 CTCs 计数阳性。CTCs 细胞在不同 NPC 分期中高表达，IV 期间充质 CTCs 阳性率高于其他分期。转移患者间充质细胞的比例表达较高。不同类型的 CTCs 中 COX-2 的表达不同。IV 期患者 CTCs 中 COX-2 的阳性率高于 II 期和 III 期患者。减少 CTCs 中表达 COX-2 与 NPC 患者的良好疗效相关。与 EBV DNA 阴性患者相比，EBV DNA 阳性患者的间充质 CTCs 和 COX-2 阳性率更高（p<0.05）。同时，治疗前 EBV DNA 阳性患者的 CTCs、间充质 CTCs、表达 COX-2 的 CTCs、表达 COX-2 的杂交 CTCs 和表达 COX-2 的间充质 CTCs 的平均数量均明显高于 EBV DNA 阴性患者（p<0.05）。
CTCs 及其 COX-2 的表达与 NPC 临床特征相关，与 Epstein-Barr 病毒 DNA 有关。减少 CTCs 中表达 COX-2 与 NPC 患者的良好疗效相关。
